31 Matching Annotations
  1. Dec 2022
    1. Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease.

      One of the few papers giving clear support to ivermectin as a prophylactic drug against covid19.

      Has been partially refuted by politifact, and accused 1st author Andrew Bryant of hiding conflict-of-interest.

    1. There was however a marked reduction of self-reported anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.

      A well-structured research about non-severe case protocol pre-announced on Jun 2020 concludes that it reduces anosmia!

    1. Based on the very low-certainty evidence for inpatients, we are still uncertain whether ivermectin prevents death or clinical worsening or increases serious adverse events, while there is low-certainty evidence that it has no beneficial effect regarding clinical improvement, viral clearance and adverse events. No evidence is available on ivermectin to prevent SARS-CoV-2 infection.

      Study of trials by german researcher is dismissive of any therapeutic value.

    1. IvermectinThis FDA-approved antiparasitic drug has demonstrated a degree of efficacy in vitro against SARS-CoV-2 infection (Caly et al., 2020; Yang et al., 2020), and uncontrolled, interventional studies have reported a degree of efficacy or no benefits (Amhed et al., 2020; Chachar et al., 2020; Khan et al., 2020). However, the NIH Panel indicates that there is insufficient evidence for COVID-19 treatment and recommended against its use (COVID-19 Treatment Guidelines Panel, 2022).

      Big position-paper from Lincei Academy focusing mostly on other drugs, is NOT dismissive of ivermectin, provides x2 for in-vitro and x3 in-vivo refs, and repeats the FDA mantra at the end.

  2. Nov 2022
    1. Even though ivermectin had no effect on viral load, SARS-Cov-2-associated pathology was greatly attenuated. IVM had a sex-dependent and compartmentalized immunomodulatory effect, preventing clinical deterioration and reducing olfactory deficit in infected animals. Importantly, ivermectin dramatically reduced the Il-6/Il-10 ratio in lung tissue, which likely accounts for the more favorable clinical presentation in treated animals. Our data support IVM as a promising anti-COVID-19 drug candidate.

      Impressive pro-ivermectin results, but paper probably has low sciscore.

    1. In conclusion, ivermectin seems to be effective to diminish MHV viral load and disease in mice, being a useful model for further understanding new therapies against coronavirus diseases.

      Impressive result for ivermectine.

    1. Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

      That's the generic's equivalent for [[paxlovid]].

  3. Aug 2022
  4. Feb 2022
  5. Jan 2022
  6. Dec 2021
  7. Nov 2021
    1. Richard Sever. (2021, October 30). The article is on ivermectin but the sunk intellectual cost fallacy has lessons for us all: "Publicly backtracking when the results refute your idea requires a very large dose of humility” Such humility has been notably lacking among Nobels and other COVID inexperts [Tweet]. @cshperspectives. https://twitter.com/cshperspectives/status/1454483988031152137

  8. Oct 2021
  9. Sep 2021
    1. Ben Collins on Twitter: “A quick thread: It’s hard to explain just how radicalized ivermectin and antivax Facebook groups have become in the last few weeks. They’re now telling people who get COVID to avoid the ICU and treat themselves, often by nebulizing hydrogen peroxide. So, how did we get here?” / Twitter. (n.d.). Retrieved September 26, 2021, from https://twitter.com/oneunderscore__/status/1441395300002848769?s=20

  10. Aug 2021
  11. Jun 2021